Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-2127 in Relapsed/Refractory B-cell Malignancies
NCT04830137Phase 1Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment), Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zelebrudomide in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM) and 5 more (11 arms), sponsored by Nurix Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 24 months, Maximum Tolerated Dose at 24 months and 2 more. Started May 2021; status: recruiting.
02
Drugs
zelebrudomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04830137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830137.